ArticleApplied biochemistry and biotechnology2026
Production of Anti-melanogenic Glucosides via Molecular Docking-guided Biotransformation of p-hydroxyphenethyl anisate.
Article in Applied biochemistry and biotechnology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
p-Hydroxyphenethyl anisate (HP) has been identified as a natural compound with whitening activity in melanoma cells and zebrafish. Considering that glycosylation can enhance the solubility, stability, and bioactivity of natural products, we investigated whether HP could serve as a substrate for glycosylation enzymes. Molecular docking predicted favorable interactions between HP and amylosucrase as well as glycosyltransferases, suggesting the potential formation of α- and β-glucosides. Enzymatic reactions confirmed the production of phenethylanisate-4'-O-α-glucoside (HP-α-glc) and phenethylanisate-4'-O-β-glucoside (HP-β-glc). The structures were validated by mass spectrometry, enzymatic digestion (HP-α-glc), or nuclear magnetic resonance spectroscopy (HP-β-glc). Biological evaluation revealed that both glucosides suppressed melanogenesis in murine B16-F1 melanoma cells at non-cytotoxic concentrations. Mechanistic studies demonstrated that HP-β-glc not only inhibited tyrosinase activity but also downregulated the expression of the microphthalmia-associated transcription factor (MITF) and tyrosinase at both the protein and mRNA levels, thereby attenuating melanogenesis through transcriptional regulation. Consistently, in vivo assays demonstrated that HP-β-glc effectively inhibited pigmentation in zebrafish embryos without inducing developmental toxicity, and its effect was comparable to that of the positive control, raspberry ketone. These findings highlight the enzymatic glycosylation of HP as a viable strategy to generate bioactive derivatives with improved functional properties. In particular, HP-β-glc retains the anti-melanogenic activity of HP, providing mechanistic evidence and preclinical validation for its potential application as a safe and effective skin-whitening agent.
Indexed as
Identifiers
42720894What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.